14.52
+0.7(+5.07%)
Currency In USD
Address
43 Thorndike Street
Cambridge, MA 02141
United States of America
Phone
617 682 0917
Website
Sector
Healthcare
Industry
Biotechnology
Employees
123
First IPO Date
January 07, 2022
| Name | Title | Pay | Year Born |
| Mr. Joshua B. Cohen | Co-Founder, Co-Chief Executive Officer & Director | 1.23M | 1992 |
| Mr. Justin B. Klee | Co-Founder, Co-Chief Executive Officer & Director | 1.23M | 1991 |
| Ms. Gina M. Mazzariello J.D. | Chief Legal Officer & General Counsel | 715,494 | 1972 |
| Mr. James M. Frates M.B.A. | Chief Financial Officer | 806,277 | 1967 |
| Dr. Jamie Timmons | Head of Global Medical Strategy & Communications | 0 | N/A |
| Ms. Linda A. Arsenault | Chief Human Resources Officer | 0 | N/A |
| Ms. Lindsey Allen | Head of Investor Relations & Communications | 0 | N/A |
| Mr. Tom Holmes | Chief Technical Operations Officer | 0 | N/A |
| Ms. Tammy Sarnelli | Global Head of Regulatory Affairs | 0 | N/A |
| Dr. Machelle Manuel Ph.D. | Vice President & Head of Global Medical Affairs | 0 | N/A |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.